However, the complexity of combinatorial approaches for ADC treatment is highlighted by the fact that the functional activity of cathepsin L is necessary in HER2 low breast cancer models for effective treatment with T-DXd [62]. This evidence concerns the gene ERBB2 and breast carcinoma.